You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,838,505


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,838,505
Title:Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
Inventor(s): Kim; Jong-Mook (Seoul, KR), Hahn; Woong (Seoul, KR)
Assignee: ViroMed Co., Ltd. (KR)
Application Number:11/957,170
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,838,505
Patent Claims:1. A method of increasing angiogenesis in a tissue of a subject comprising administering to the tissue of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising (a) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA, (b) a polynucleotide that has the same sequence as intron 4 of a HGF gene or a fragment thereof, and (c) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA; wherein (b) is located between (a) and (c); and the HGF construct simultaneously encodes two heterotypes of human HGF, wherein said administration results in increased angiogenesis in said tissue.

2. The method of claim 1, wherein the polynucleotide of (b) has the same sequence as the full intron 4 of the human HGF gene.

3. The method of claim 2, wherein said hybrid HGF construct comprises a nucleotide sequence comprising SEQ ID NO: 2.

4. The method of claim 1, wherein the polynucleotide of (b) has the same sequence as a fragment of intron 4 of the human HGF gene.

5. The method of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO: 19.

6. The method of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO: 20.

7. The method of claim 4, wherein said hybrid HGF construct comprises SEQ ID NO: 21.

8. The method of claim 1, wherein said hybrid HGF construct is a vector.

9. The method of claim 8, wherein said vector further comprises one or more sequences for regulating expression, a self-replication sequence, or a secretory signal.

10. The method of claim 8, wherein said vector is selected from the group consisting of: pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X6, pCK-HGF-X7, pCK-HGF-X8, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8.

11. The method of claim 1, wherein said hybrid HGF construct is administered intramuscularly to said tissue.

12. The method of claim 1, wherein said tissue is an ischemic limb.

13. A method of increasing angiogenesis in a tissue of a subject comprising administering to the tissue of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO: 2, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF, wherein said administration results in increased angiogenesis in said tissue.

14. The method of claim 13, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO:2.

15. A method of increasing angiogenesis in a tissue of a subject comprising administering to the tissue of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO: 19, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF, wherein said administration results in increased angiogenesis in said tissue.

16. The method of claim 15, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO: 19.

17. A method of increasing angiogenesis in a tissue of a subject comprising administering to the tissue of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO: 20, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF, wherein said administration results in increased angiogenesis in said tissue.

18. The method of claim 17, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO: 20.

19. A method of increasing angiogenesis in a tissue of a subject comprising administering to the tissue of said subject a hybrid Hepatocyte Growth Factor (HGF) construct comprising a polynucleotide having a nucleotide sequence not less than 90% identical to SEQ ID NO: 21, wherein the polynucleotide having said nucleotide sequence simultaneously encodes two heterotypes of human HGF, wherein said administration results in increased angiogenesis in said tissue.

20. The method of claim 19, wherein said nucleotide sequence is not less than 95% identical to SEQ ID NO: 21.

Details for Patent 7,838,505

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2022-03-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2022-03-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2022-03-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.